SCHEMBL1461063

SCHEMBL1461063

O=POc1ccc(Cl)cc1-c1nc2ccc(Cl)cc2c(=O)[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GUSB P08236 4/20 0.51
TNKS O95271 2/20 0.49
TNKS2 Q9H2K2 2/20 0.49
PARP1 P09874 2/20 0.49
CYP1A1 P04798 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP1B1 Q16678 1/20 0.46
KDM4E B2RXH2 2/20 0.45
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44
TUBA3C P0DPH7 2/20 0.44
TUBA1B P68363 2/20 0.44
TUBA4A P68366 2/20 0.44
TUBB4B P68371 2/20 0.44
TUBB3 Q13509 2/20 0.44
TUBB2A Q13885 2/20 0.44
TUBB8 Q3ZCM7 2/20 0.44
TUBA3E Q6PEY2 2/20 0.44
TUBA1A Q71U36 2/20 0.44
TUBA1C Q9BQE3 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL9010817 0.99 GUSB (0.50) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL13953178 0.86 AMY1A (0.57) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL1232936 0.84 TNKS (0.49) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL29351150 0.84 TNKS (0.49) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL23732260 0.84 TNKS (0.57) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL3660038 0.83 TNKS (0.48) GUSBTNKSTNKS2PARP1CYP1A1
Ammonia Solution, Strong SCHEMBL9010745 0.83 TNKS (0.48) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL13932609 0.82 TNKS (0.50) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL15964871 0.82 TNKS (0.50) GUSBTNKSTNKS2PARP1CYP1A1
SCHEMBL3660037 0.81 GUSB (0.48) GUSBTNKSTNKS2PARP1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240044893-A1 ULTRASENSITIVE SENSING METHOD FOR DETECTION OF BIOMOLECULES UNIV CONNECTICUT (US) 2024-02-08 US claimed
WO-2024020471-A2 TOPOGRAPHIC MODULATION OF ENZYMATIC REACTION AFFORDS ULTRASENSITIVE COMPARTMENT-FREE DIGITAL IMMUNOASSAYS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2024-01-25 WO claimed
EP-2972345-B1 A FLOW-THROUGH CELL COUNTING ASSAY ALLIED INNOVATIVE SYSTEMS LLC (US) 2018-01-17 EP claimed
EP-2972345-A1 A FLOW-THROUGH CELL COUNTING ASSAY Allied Innovative Systems, LLC (US) 2016-01-20 EP claimed
US-9097712-B2 Flow-through cell counting assay ALLIED INNOVATIVE SYSTEMS LLC (US) 2015-08-04 US claimed
US-20140349893-A1 LABELING OF IMMOBILIZED PROTEINS USING DIPYRROMETHENEBORON DIFLUORIDE DYES Life Technologies Corporation (US) 2014-11-27 US claimed
WO-2014149310-A1 A FLOW-THROUGH CELL COUNTING ASSAY ALLIED INNOVATIVE SYSTEMS, LLC (US) 2014-09-25 WO claimed
US-20140273018-A1 FLOW-THROUGH CELL COUNTING ASSAY ALLIED INNOVATIVE SYSTEMS, LLC (US) 2014-09-18 US claimed
JP-4643263-B2 2011-03-02 JP claimed
JP-4643262-B2 2011-03-02 JP claimed
WO-2004020604-A2 ALLELE SPECIFIC PRIMER EXTENSION AMERSHAM BIOSCIENCES CORP (US) 2004-03-11 WO claimed
US-20040048301-A1 Allele specific primer extension GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2004-03-11 US claimed
WO-2004020603-A2 ANALYTE DETECTION AMERSHAM BIOSCIENCES CORP (US) 2004-03-11 WO claimed
US-20030162213-A1 Terminal-phosphate-labeled nucleotides and methods of use GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-08-28 US claimed
US-20030124576-A1 Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-07-03 US claimed
US-20030096253-A1 Single nucleotide amplification and detection by polymerase GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-05-22 US claimed
US-20030077610-A1 Terminal-phosphate-labeled nucleotides and methods of use GLOBAL LIFE SCIENCES SOLUTIONS USA LLC 2003-04-24 US claimed
WO-2003020984-A2 TERMINAL-PHOSPHATE-LABELED NUCLEOTIDES AND METHODS OF USE AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
WO-2003020734-A2 LABELED NUCLEOSIDE POLYPHOSPHATES AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed
WO-2003020891-A2 SINGLE NUCLEOTIDE AMPLIFICATION AND DETECTION BY POLYMERASE AMERSHAM BIOSCIENCES CORP (US) 2003-03-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030124576-A1 Such as (3-cyanocoumarinyl)dideoxyadenosine-5'-triphosphate which reacts with phosophatase to create detectable species (chemiluminescence, fluorescence); substrates for nucleic acid polymerases PNP, RNGTT, MTAP GUSB 396/4885TNKS 1006/4885TNKS2 1317/4885
US-20030077610-A1 Terminal-phosphate-labeled nucleotides and methods of use RNGTT, DNTT, PNP GUSB 288/4885TNKS 429/4885TNKS2 650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.